| Literature DB >> 33317592 |
Yang Qi-Yue1, Zhang Ting2, He Ya-Nan2, Huang Sheng-Jie2, Deng Xuan2, Han Li3,4, Xie Chun-Guang5.
Abstract
BACKGROUND: Indigo naturalis is a blue dye in ancient, as well as an extensive used traditional Chinese medicine. It has a wide spectrum of pharmacological properties and can be used to treat numerous ailments such as leukemia, psoriasis, and ulcerative colitis. This article aims to expand our understanding of indigo naturalis in terms of its chemical constituents, pharmacological action and clinical applications.Entities:
Keywords: Anti-inflammation; Indigo naturalis; Indole alkaloids; Leukemia; Psoriasis; Ulcerative colitis
Year: 2020 PMID: 33317592 PMCID: PMC7734464 DOI: 10.1186/s13020-020-00406-x
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 5.455
Fig. 1The manufacturing process of Indigo naturalis
Fig. 2The reaction mechanism of indigo and indirubin.
Fig. 3Structural formula of some chemical constituents in indigo naturalis
Clinical experiment of treating psoriasis with indigo naturalis
| Drugs | Clinic types of experiments | Types of psoriasis | Number of examinees | Usage time | Results | Refs. |
|---|---|---|---|---|---|---|
| Indigo naturalis oil extract | A non-controlled pilot study | Nail psoriasis | n = 28 | 24 weeks | The Nail Psoriasis Severity Index (NAPSI) decreased from 36.1 ± 14.7 to 14.9 ± 11.1, and the average Nasi score decreased from 11.7 ± 3.9 to 3.6 ± 3.2 | [ |
| Indigo naturalis ointment | A randomized, double-blind, placebo-controlled study | Moderate psoriasis | n = 24 (drug:16, placebo: 8) | 8 weeks | In 56.3% of patients, the psoriasis area and severity index scores were improved by 75%, and IL-17 in skin genes of these patients was significantly down regulated compared with placebo | [ |
| Indigo naturalis ointment or vehicle ointment | A randomized, observer-blind, vehicle-controlled study | Recalcitrant psoriasis | n = 42 | 12 weeks | Compared with placebo, the scores of erythema, scale and lump and plaque area of indigo naturalis in treatment site were significantly reduced. The symptoms of psoriasis disappeared or nearly disappeared in 74% of patients with indigo naturalis | [ |
| Indigo naturalis composite ointment | – | Pediatric psoriasis | 8-year-old boy | 8 weeks | After treating with indigo naturalis composite ointment, the lesions of systemic psoriasis disappeared completely, and the affected body surface decreased from nearly 80–0%. Remission has lasted for over 2 years without any adverse reaction | [ |
| Indigo naturalis oil extract drops | – | Pediatric nail psoriasis with periodic pustular eruption | A 13-year-old girl | 6 months | After treat in one month, the pustulation of the nails and the crusted, keratotic erythematous lesions disappeared. A completely normal nail unit without Beau’s lines was achieved after 6 months without any adverse reaction Remission has lasted for over 1 year | [ |
Clinical experiment of indigo naturalis in treating UC
| Drugs | Clinic types of experiments | Number of examinees | Usage time | Results | Adverse reactions | Refs. |
|---|---|---|---|---|---|---|
| Indigo naturalis | Retrospective observational study | n = 14 | 8 weeks | In 10 active UC patients 50% had clinical response and 40% achieved clinical remission. Rachmilewitz endoscopic index (REI), and UC endoscopy index of severity (UCEIS). the Mayo endoscopic subscore (MES) decreased from 2 (2–3) to 1 (1–2), the Rachmilewitz endoscopic index (REI) decreased from 7 (5.5–11) to 3 (1–7), and the UC endoscopy index (UCEIS) of severity decreased from 3 (3-4.5) to 1 (0.5–3.5) | One patient developed right colitis with intestinal wall thickening and edema | [ |
| Indigo naturalis oil suppository | Open-label, single-center, prospective pilot study | n = 10 | 4 weeks | 30% of patients achieved clinical remission, 40% of patients had mucosal healing. Mucosal healing was observed in 80% of patients with MES in the Rectum (R-MES) score of 2, but not in patients with scores of 3 | One patient developed perianal pain | [ |
| Indigo naturalis | A multicenter, double-blind trial | n = 86 | 8 weeks | The clinical response of UC was correlated with the oral dose of indigo naturalis. 13.6% of patients had clinical response to placebo; 69.6% to 0.5 g indigo naturalis; 75.0% to 1.0 g indigo naturalis and 81.0% to 2.0 g indigo naturalis. At week 8, 56.6% patients with 0.5 g, 60% with 1.0 g and 47.6% with 2.0 g indigo naturalis received clinical relief compared to 13.6% placebo | Mild liver dysfunction was observed in 10 patients taking indigo naturalis, but there were no significant adverse reactions. Unfortunately, the experiment was terminated because a patient took indigo naturalis by heself and developed pulmonary hypertension | [ |
| Indigo naturalis | Retrospective observational study | n = 17 in UC and n = 8 in Crohn’s disease (CD) | 8 weeks | There are 94.1% and 88.2% in UC and 37.5% and 25.0% in CD receiving Clinical response and clinical remission, respectively | During follow-up, 10 patients developed adverse reactions, and 3 patients experienced severe adverse reactions, including 2 cases of acute colitis requiring hospitalization and 1 case of acute colitis intussusception requiring surgical treatment | [ |
52 weeks And 104 weeks | Through non-responders imputation analyses at weeks 52 and 104, the clinical remission rates were 76.4% and 70.4% in UC patients and 25.0% and 25.0% in CD patients |